Study summary
Retifanlimab shrank more than half of advanced Merkel cell cancers
54.5%had their tumors shrink
What was tested
Retifanlimab, an immunotherapy given every 4 weeks, in advanced Merkel cell carcinoma not treated with chemotherapy. No comparison group.
What they found
- Tumors shrank in 54.5%, including 17.8% whose cancer disappeared.
- 63% were alive at 3 years.
- Serious immune side effects occurred in about 11%.
What it means
A third approved immunotherapy option, dosed every 4 weeks.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.